Duovir-N 

Duovir-N is a tablet that contains a combination of three antiretroviral medications:

• Lamivudine (150mg): a nucleoside reverse transcriptase inhibitor (NRTI)
• Zidovudine (100mg): a nucleoside reverse transcriptase inhibitor (NRTI)
• Nevirapine (200mg): a non-nucleoside reverse transcriptase inhibitor (NNRTI)

Mechanism of Action:

The combination of Lamivudine, Zidovudine, and Nevirapine works in the following way:

• Lamivudine and Zidovudine inhibit the activity of HIV reverse transcriptase, an enzyme necessary for the virus to replicate.
• Nevirapine inhibits the activity of HIV reverse transcriptase by binding to the enzyme and preventing it from replicating the viral genome.

Uses:

Duovir-N is used to treat HIV infection in adults and adolescents. It is recommended for patients who have not previously received antiretroviral therapy or who have failed other antiretroviral regimens.

Dosage:

The recommended dosage of Duovir-N is one tablet twice daily, taken with food.

Side Effects:

Common side effects of Duovir-N include:

• Headache
• Nausea
• Vomiting
• Diarrhea
• Fatigue
• Dizziness
• Insomnia
• Rash
• Abnormal dreams
• Increased blood lipids
• Neuropathy (nerve damage)
• Lactic acidosis (build-up of lactic acid in the blood)

Recommendation:

Duovir-N should be used under the guidance of a healthcare professional. Patients should be monitored regularly for liver function tests, lipid profiles, and glucose levels.

Important Note:

• Duovir-N is not recommended for use in patients with severe liver disease (Child-Pugh C).
• Patients with pre-existing kidney disease should be monitored closely for signs of kidney damage or toxicity.
• Patients taking other medications, including antiretroviral agents, may be at risk for interactions with Duovir-N.
• The safety and efficacy of Duovir-N in pregnant or lactating women have not been established.
• Patients should be counseled on the importance of taking concomitant therapy as prescribed by their healthcare provider.
• Patients should be monitored for neuropsychiatric symptoms, such as depression, anxiety, and sleep disorders.

Special Precautions:

• Duovir-N should be taken with food to improve absorption.
• Patients with diabetes should be monitored closely for changes in blood glucose levels.
• Patients with pre-existing kidney disease should be monitored closely for signs of kidney damage or toxicity.
• Patients with liver disease should be monitored closely for signs of liver damage or toxicity.
• Patients taking other medications that may interact with Duovir-N should be monitored closely for signs of toxicity or adverse effects.

Contraindications:

Duovir-N is contraindicated in patients who are allergic to any of its ingredients. It is also contraindicated in patients with severe liver disease (Child-Pugh C).

Clinical Trials:

Duovir-N has been studied in clinical trials in combination with other antiretroviral agents. The results of these trials have shown that Duovir-N is effective in suppressing HIV replication and improving patient outcomes.